doi:10.2337/dc24-SINT Davies MJ, et al
Verma S, McGuire DK, Bain SC, Bhatt DL, Leiter LA, Mazer CD et al (2020) Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: results of the LEADER and SUSTAIN 6 trials
Veeravich Jaruvongvanich For more information please contact: Digestive Disease (GI) Center 8:00 am to 8:00 pm (BKK Time) Hot line tel
Patient Selection Criteria Not all individuals struggling with weight management are suitable candidates for Tesofensine or GLP-1 agonists
Studies have shown that dietary protein triggers substantial GLP-1 release, with whey protein demonstrating especially pronounced effects
The workout you miss when you feel terrible is infinitely better than the injury you sustain by pushing through when your body is compromised